New drug plus enzalutamide for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug (TYK-00540) combined with enzalutamide for men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It may be an option if you have tried only one other newer hormone treatment and it failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your prostate cancer has spread to other parts of the body (like bones or organs) and is no longer responding to hormone therapy that lowers testosterone.
- You have tried only one newer hormone therapy (like abiraterone or apalutamide) and it stopped working—but you have never taken enzalutamide.
- Your general health is good enough to perform daily activities without help (ECOG score 0 or 1).
- Your liver, kidney, and blood counts are within healthy ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
This study tests a new drug, TY-302, combined with abiraterone (a standard hormone therapy) for men with metastatic castration-resistant prostate cancer that has stopped responding to one prior new hormone therapy. The goal is to see if the combination can help control the disease.
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
This study tests a new drug called mevrometostat combined with enzalutamide in men whose prostate cancer has spread and is no longer responding to previous hormone-blocking treatments. The goal is to see if adding mevrometostat helps slow cancer growth when enzalutamide alone is no longer working.
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Hear when a new mCRPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.